Annual CFI
$64.55 M
+$29.79 M+85.72%
December 31, 2024
Summary
- As of March 12, 2025, SWTX annual cash flow from investing activities is $64.55 million, with the most recent change of +$29.79 million (+85.72%) on December 31, 2024.
- During the last 3 years, SWTX annual CFI has fallen by -$19.05 million (-22.79%).
- SWTX annual CFI is now -22.79% below its all-time high of $83.59 million, reached on December 31, 2021.
Performance
SWTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$14.14 M
-$14.50 M-50.62%
December 31, 2024
Summary
- As of March 12, 2025, SWTX quarterly cash flow from investing activities is $14.14 million, with the most recent change of -$14.50 million (-50.62%) on December 31, 2024.
- Over the past year, SWTX quarterly CFI has increased by +$13.86 million (+4794.46%).
- SWTX quarterly CFI is now -85.65% below its all-time high of $98.60 million, reached on March 31, 2023.
Performance
SWTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
$64.55 M
+$173.35 M+159.32%
December 31, 2024
Summary
- As of March 12, 2025, SWTX TTM cash flow from investing activities is $64.55 million, with the most recent change of +$173.35 million (+159.32%) on December 31, 2024.
- Over the past year, SWTX TTM CFI has increased by +$167.40 million (+162.75%).
- SWTX TTM CFI is now -67.00% below its all-time high of $195.59 million, reached on September 30, 2022.
Performance
SWTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
SWTX Cash From Investing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +85.7% | +4794.5% | +162.8% |
3 y3 years | -22.8% | +4794.5% | +162.8% |
5 y5 years | +1615.1% | +4794.5% | +162.8% |
SWTX Cash From Investing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -22.8% | +129.9% | -85.7% | +104.0% | -67.0% | +129.9% |
5 y | 5-year | -22.8% | +115.4% | -85.7% | +104.0% | -67.0% | +114.4% |
alltime | all time | -22.8% | +115.4% | -85.7% | +104.0% | -67.0% | +114.4% |
SpringWorks Therapeutics Cash From Investing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | $64.55 M(+85.7%) | $14.14 M(-50.6%) | $64.55 M(-159.3%) |
Sep 2024 | - | $28.65 M(+9812.8%) | -$108.81 M(+5.8%) |
Jun 2024 | - | $289.00 K(-98.7%) | -$102.85 M(+142.7%) |
Mar 2024 | - | $21.46 M(-113.5%) | -$42.39 M(-222.0%) |
Dec 2023 | $34.75 M(-116.1%) | -$159.21 M(-560.1%) | $34.75 M(-121.6%) |
Sep 2023 | - | $34.60 M(-43.1%) | -$161.05 M(+47.2%) |
Jun 2023 | - | $60.76 M(-38.4%) | -$109.42 M(-23.7%) |
Mar 2023 | - | $98.60 M(-127.8%) | -$143.42 M(-33.5%) |
Dec 2022 | -$215.60 M(-357.9%) | -$355.01 M(-511.7%) | -$215.60 M(-210.2%) |
Sep 2022 | - | $86.23 M(+222.3%) | $195.59 M(+34.8%) |
Jun 2022 | - | $26.76 M(+1.3%) | $145.15 M(+3.0%) |
Mar 2022 | - | $26.42 M(-53.0%) | $140.93 M(+68.6%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2021 | $83.59 M(-120.0%) | $56.18 M(+57.0%) | $83.59 M(-142.8%) |
Sep 2021 | - | $35.78 M(+58.7%) | -$195.37 M(-45.5%) |
Jun 2021 | - | $22.54 M(-172.9%) | -$358.72 M(-20.2%) |
Mar 2021 | - | -$30.92 M(-86.1%) | -$449.59 M(+7.3%) |
Dec 2020 | -$418.83 M(+9731.7%) | -$222.78 M(+74.6%) | -$418.83 M(+113.5%) |
Sep 2020 | - | -$127.56 M(+86.7%) | -$196.18 M(+185.6%) |
Jun 2020 | - | -$68.33 M(>+9900.0%) | -$68.70 M(+1551.9%) |
Mar 2020 | - | -$160.00 K(+23.1%) | -$4.16 M(-2.4%) |
Dec 2019 | -$4.26 M(+1353.9%) | -$130.00 K(+54.8%) | -$4.26 M(+3.1%) |
Sep 2019 | - | -$84.00 K(-97.8%) | -$4.13 M(+2.1%) |
Jun 2019 | - | -$3.79 M(+1350.2%) | -$4.05 M(+1450.2%) |
Mar 2019 | - | -$261.00 K | -$261.00 K |
Dec 2018 | -$293.00 K | - | - |
FAQ
- What is SpringWorks Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics annual CFI year-on-year change?
- What is SpringWorks Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics quarterly CFI year-on-year change?
- What is SpringWorks Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics TTM CFI year-on-year change?
What is SpringWorks Therapeutics annual cash flow from investing activities?
The current annual CFI of SWTX is $64.55 M
What is the all time high annual CFI for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high annual cash flow from investing activities is $83.59 M
What is SpringWorks Therapeutics annual CFI year-on-year change?
Over the past year, SWTX annual cash flow from investing activities has changed by +$29.79 M (+85.72%)
What is SpringWorks Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of SWTX is $14.14 M
What is the all time high quarterly CFI for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high quarterly cash flow from investing activities is $98.60 M
What is SpringWorks Therapeutics quarterly CFI year-on-year change?
Over the past year, SWTX quarterly cash flow from investing activities has changed by +$13.86 M (+4794.46%)
What is SpringWorks Therapeutics TTM cash flow from investing activities?
The current TTM CFI of SWTX is $64.55 M
What is the all time high TTM CFI for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high TTM cash flow from investing activities is $195.59 M
What is SpringWorks Therapeutics TTM CFI year-on-year change?
Over the past year, SWTX TTM cash flow from investing activities has changed by +$167.40 M (+162.75%)